Retatrutide vs AOD-9604
Side-by-side comparison of Retatrutide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | Triple GIP/GLP-1/Glucagon Receptor Agonist | hGH C-terminal Fragment |
| Amino acids | — | 16 |
| Molecular weight | — | 1,815.1 Da |
| Half-life | ~6 days | ~30 min |
| Route(s) | Subcutaneous injection | Subcutaneous, Oral (research) |
| Mechanism & Research | ||
| Primary mechanism | Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… |
| Research status | Phase 3 Trial | Research Compound |
| Evidence summary | Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… |
| Protocol & Dosing | ||
| Typical dose | 2mg → 12mg weekly (titration) | 300–500 mcg/day |
| Frequency | Once weekly | Once daily |
| Duration | Ongoing (Phase 3) | 8–12 weeks |
| Timing | Same day each week | Pre-workout or morning on empty stomach (for metabolic effects) |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Tirzepatide, Semaglutide, AOD-9604 | Semaglutide, Ipamorelin, Tesamorelin |
| Full profile | Read full Retatrutide profile → | Read full AOD-9604 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.